ClinicalTrials.gg
RecruitingNCT06859710THC-REDUXUpdated Nov 18, 2026

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

A Phase 1 interventional study of Placebo and THC in Abuse, Drug and Pain, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Substance-Related Disorders by University of California, Los Angeles — 5 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · University of California, Los Angeles.

Planned enrollment
39th of 48
30 · median 125
Started
2025
with 2 others
Phase 1
10 of 51
3 open now
Registered
49th of 51
by date

Among the 51 studies in Substance-Related Disorders by University of California, Los Angeles, this one is the 39th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 1, and was the 49th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

5 of the 51 studies in Substance-Related Disorders by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Substance-Related Disorders by University of California, Los Angeles, or all of them as a file.
02

Study summary

The purpose of this research is to assess the impact of CBD on the effects of THC.

Read the detailed description

Some evidence indicates that cannabidiol (CBD), a non-intoxicating cannabis component, might mitigate certain effects of THC. This study will examine possible roles for CBD in modulating THC's adverse and analgesic effects.

03

Conditions studied

  • Abuse, Drug
  • Pain

Keywords

  • Cannabis
  • THC
  • CBD
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report cannabis use 1-7 days per week over the month prior to screening
  • Not currently seeking treatment for their cannabis use
  • History of inhaled cannabis use
  • Have a from 18.5 - 34 kg/m2
  • Able to perform all study procedures
  • Must be using a (hormonal or barrier methods)

Exclusion criteria

Exclusion Criteria:

  • Meeting criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
  • Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide .
  • Report using other illicit drugs in the prior 4 weeks
  • Current pain
  • Pregnancy
  • Currently enrolled in another research protocol
  • Not using a method (hormonal or barrier methods)
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
  • Not able to speak and read English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    0 mg THC, 0 mg CBD

    Drug: Placebo

  • Active comparator
    THC

    20 mg THC, 0 mg CBD

    Drug: THC

  • Active comparator
    CBD 20

    0 mg THC, 20 mg CBD

    Drug: CBD 20 mg

  • Active comparator
    CBD 40

    0 mg THC, 40 mg CBD

    Drug: CBD 40 mg

  • Active comparator
    CBD 80

    0 mg THC, 80 mg CBD

    Drug: CBD 80 mg

  • Active comparator
    THC with CBD 20

    20 mg THC, 20 mg CBD

    Drug: THC · Drug: CBD 20 mg

  • Active comparator
    THC with CBD 40

    20 mg THC, 40 mg CBD

    Drug: THC · Drug: CBD 40 mg

  • Active comparator
    THC with CBD 80

    20 mg THC, 80 mg CBD

    Drug: THC · Drug: CBD 80 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Subject-rated drug effects of abuse liability

    Subject ratings of "Good Drug Effect" as measured using a visual analog scale (1-100 mm)

    Time frame: 3 hours

  2. Analgesia as measured using the Cold Pressor Test

    Pain threshold assessed using the Cold Pressor Test (percent baseline)

    Time frame: 3 hours

  3. Behavioral task performance as assessed by the DRUID App Score

    Trough composite scores on the DRUID App

    Time frame: 3 hours

  4. Pharmacokinetics of THC

    Peak plasma levels of THC (ng/ml)

    Time frame: 3 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 30 non-industry phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 21 months is below that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 5, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06859710
Responsible party
Ziva D. Cooper, PhD (Professor, University of California, Los Angeles) — Principal investigator
First posted
Mar 5, 2025
Start date
Nov 5, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Ziva Cooper, PhD
Contact
zcooper@mednet.ucla.edu
310-206-9942
Vincent Acebo
Contact
vacebo@mednet.ucla.edu
310-983-3417
Ziva Cooper, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dronabinol · Cannabidiol

Start the discussion